Anti‐IgE antibodies for the treatment of IgE‐mediated allergic diseases
TW Chang, PC Wu, CL Hsu, AF Hung - Advances in immunology, 2007 - Elsevier
The pharmacological purposes of the anti‐IgE therapy are to neutralize IgE and to inhibit its
production to attenuate type I hypersensitivity reactions. The therapy is based on humanized
IgG1antibodies that bind to free IgE and to membrane‐bound IgE on B cells, but not to IgE
bound by the high‐affinity IgE. Fc receptors on basophils and mast cells or by the low‐affinity
IgE. Fc receptors on B cells. After nearly 20 years since inception, therapeutic anti‐IgE
antibodies (anti‐IgE) have been studied in about 30 Phase II and III clinical trials in many …
production to attenuate type I hypersensitivity reactions. The therapy is based on humanized
IgG1antibodies that bind to free IgE and to membrane‐bound IgE on B cells, but not to IgE
bound by the high‐affinity IgE. Fc receptors on basophils and mast cells or by the low‐affinity
IgE. Fc receptors on B cells. After nearly 20 years since inception, therapeutic anti‐IgE
antibodies (anti‐IgE) have been studied in about 30 Phase II and III clinical trials in many …